ClinicalTrials.gg
TerminatedNCT01177540Updated Jun 28, 2022Results posted

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

A Phase 2 interventional study of Decitabine and Decitabine in Pediatric Acute Myelogenous Leukemia (AML), sponsored by Eisai Inc.. Terminated at 22 sites in 3 countries. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
1 Year to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Enrollment
72nd of 120
25 · median 32
Started
2011
with 6 others
Phase 2
53 of 121
10 open now
Registered
27th of 121
by date
Lead sponsor
4 of 121
Eisai Inc.

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 72nd largest by enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2011, is one of 53 in phase 2, and was the 27th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to provide data on the activity of a standard daunorubicin, cytarabine, and etoposide (ADE) induction plus epigenetic priming with decitabine as assessed by standard measures of complete remission (CR), leukemia free survival (LFS) and overall survival (OS), as well as, on minimal residual disease (MRD). It will also provide necessary data on the safety and Pharmacokinetics (PK) of decitabine in pediatric patients that is currently unavailable.

03

Conditions studied

  • Pediatric Acute Myelogenous Leukemia (AML)
04

Who can participate

Ages eligible
1 Year to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age 1 to 16 years, inclusive
  2. Females of must have a negative serum beta human chorionic gonadotropin ( B-hCG) at Visit 1 (Screening) and a negative urine pregnancy test prior to starting study drugs (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use a highly effective method of (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine devise (IUD), or have a vasectomised partner) for at least one menstrual cycle prior to starting study drug(s) and throughout the Randomization Phase or 30 days after the last dose of study drug. Those females using hormonal contraceptives must also be using an additional approved method of contraception (as described previously)
  3. Sexually mature male patients who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the Randomization Phase and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously)
  4. Diagnosis of acute myelogenous leukemia ( AML) (bone marrow or peripheral blood blasts greater than or equal to 20%)
  5. Adequate cardiac function as defined by an echocardiogram or multiple gated acquisition () scan demonstrating an ejection fraction greater than 50%
  6. Are willing and able to comply with all aspects of the protocol
  7. Provide written from subject's guardian or legally authorized representative and child assent (if applicable).

Exclusion criteria

Exclusion Criteria

  1. Females who are pregnant (positive B-hCG test) or lactating
  2. History of chronic myelogenous leukemia (CML) [t(9;22)]
  3. Acute promyelocytic leukemia (M3 subtype in French-American-British [FAB] classification)
  4. Known central nervous system (CNS) leukemia
  5. AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome, or Diamond-Blackfan anemia
  6. White blood cell (WBC) count greater than 100,000/mm3
  7. Serum creatinine greater than 2.5 mg/dL
  8. (ALT) greater than 5 x (ULN) and/or total greater than 3 x ULN
  9. Prior chemotherapy (other than hydroxyurea) or radiation therapy for AML
  10. Known to be (HIV) positive
  11. Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject's ability to safely complete the study
  12. The Investigator believes the subject to be medically unfit to receive the study drug or unsuitable for any other reason
  13. Subject with to decitabine, daunorubicin, cytarabine, or etoposide
  14. Has participated in a drug trial in the last 4 weeks.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: Decitabine

  • Experimental
    Arm B

    Drug: Decitabine

Interventions

  • 5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).

  • Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Morphologic Complete Remission (CR)

    Disease response measurements were based on bone marrow evaluations (biopsies, aspirates, or both) performed by local pathology laboratories and assessed by study investigators. A designation of CR required that the participant achieve a morphologic leukemia-free state and have an absolute neutrophil count (ANC) greater than 1000 per microliter (/mcL) and a platelet count greater than 100,000/mcL.

    Time frame: Day 50

Secondary outcomes

  1. DNA Methylation

    Bone marrow samples were obtained at baseline and completion of induction therapy. DNA was extracted, and global DNA methylation was evaluated using the Infinium® Human Methylation450® BeadChip Array according to the manufacturer's protocol (Illumina, San Diego, California). Paired differential methylation analysis of end-induction marrows to participant matched screening marrows was performed to identify differentially methylated cytosines followed by guanine residue (CpG) loci (DML). A paired Wilcoxon rank test was conducted to compare end-induction marrows with diagnostic marrows within each arm to identify loci considered statistically significant and differentially methylated. Three different behaviors were defined: 'hypermethylation' (increased intensity in the tumor), 'hypomethylation' (decreased intensity in the tumor) and 'no change' (no substantial differences of intensity).

    Time frame: Baseline up to completion of induction therapy (Day 15)

  2. Leukemia-free Survival (LFS)

    LFS was defined as time from CR until the recurrence of leukemia (greater than or equal to \[\>=\] 5% bone marrow blasts, reappearance of peripheral blasts or the appearance of new dysplastic changes, or death, whichever occurred first). For participants who did not achieve a CR, LFS is set to zero days. For participants with CR who do not have leukemic recurrence or death, data for LFS was censored on the date of the last follow-up bone marrow or hematology examination, whichever is later. LFS was analyzed using Kaplan-Meier method.

    Time frame: Baseline to recurrence of Leukemia or Death (up to 2 years 5 months)

  3. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of study treatment to the date of death from any cause. OS was analyzed using Kaplan-Meier method.

    Time frame: Baseline to Date of Death (up to 2 years 5 months)

  4. Percentage of Participants With Minimal Residual Disease (MRD) at Baseline and Day 50

    After induction chemotherapy, based on bone marrow biopsies. No formal statistical analyses of MRD were performed for this study.

    Time frame: Baseline and Day 50

  5. Time to CR

    Disease response measurements were based on bone marrow evaluations (biopsies, aspirates, or both) performed by local pathology laboratories an assessed by study investigators. CR: requires that the participant achieved a morphologic leukemia-free state and had an ANC \>1000/mcL and platelets \>100,000/mcL. Hemoglobin concentration or hematocrit had no bearing on remission status, although the participant had to be independent of transfusions. Kaplan-Meier curves were used to describe time to CR.

    Time frame: Randomization to Day 50

  6. Time to Neutrophil Recovery

    Blood sampling was used to determine recovery, and is defined as less than or equal to 1000 per cubic millimeter (/mm\^3) for absolute neutrophil count (ANC). Summarized using Kaplan-Meier product limit estimators.

    Time frame: Baseline up to Day 50

  7. Time to Platelet Recovery

    Blood sampling was used to determine recovery and is defined as less than or equal to 100,000/mm\^3 for platelet count. Summarized using Kaplan-Meier product limit estimators.

    Time frame: Baseline up to Day 38

07

Results

Posted Jun 28, 2022
Limitations and caveats
The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.

Participant flow

Participants took part in the study at 11 investigative sites in Australia, Canada and the United States from 3 March 2011 to 19 July 2013.

Participant flow — Overall Study
MilestoneTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Started1114
Completed1014
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants With Morphologic Complete Remission (CR)

Disease response measurements were based on bone marrow evaluations (biopsies, aspirates, or both) performed by local pathology laboratories and assessed by study investigators. A designation of CR required that the participant achieve a morphologic leukemia-free state and have an absolute neutrophil count (ANC) greater than 1000 per microliter (/mcL) and a platelet count greater than 100,000/mcL.

Time frame:
Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Morphologic Complete Remission (CR)
percentage of participantsTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Percentage of Participants With Morphologic Complete Remission (CR)27.3 (6.0 to 61.0)50.0 (23.0 to 77.0)
SecondaryDNA Methylation

Bone marrow samples were obtained at baseline and completion of induction therapy. DNA was extracted, and global DNA methylation was evaluated using the Infinium® Human Methylation450® BeadChip Array according to the manufacturer's protocol (Illumina, San Diego, California). Paired differential methylation analysis of end-induction marrows to participant matched screening marrows was performed to identify differentially methylated cytosines followed by guanine residue (CpG) loci (DML). A paired Wilcoxon rank test was conducted to compare end-induction marrows with diagnostic marrows within each arm to identify loci considered statistically significant and differentially methylated. Three different behaviors were defined: 'hypermethylation' (increased intensity in the tumor), 'hypomethylation' (decreased intensity in the tumor) and 'no change' (no substantial differences of intensity).

Time frame:
Baseline up to completion of induction therapy (Day 15)
Reported as:
Count of units · Loci
DNA Methylation
LociTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Hypomethylated DML4134785
Hypermethylated DML2856305
SecondaryLeukemia-free Survival (LFS)

LFS was defined as time from CR until the recurrence of leukemia (greater than or equal to \[\>=\] 5% bone marrow blasts, reappearance of peripheral blasts or the appearance of new dysplastic changes, or death, whichever occurred first). For participants who did not achieve a CR, LFS is set to zero days. For participants with CR who do not have leukemic recurrence or death, data for LFS was censored on the date of the last follow-up bone marrow or hematology examination, whichever is later. LFS was analyzed using Kaplan-Meier method.

Time frame:
Baseline to recurrence of Leukemia or Death (up to 2 years 5 months)
Reported as:
Median · days
Leukemia-free Survival (LFS)
daysTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Leukemia-free Survival (LFS)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of study treatment to the date of death from any cause. OS was analyzed using Kaplan-Meier method.

Time frame:
Baseline to Date of Death (up to 2 years 5 months)
Reported as:
Median · months
Overall Survival (OS)
monthsTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Overall Survival (OS)NA (6.7 to 24.5)NA (6.2 to 26.2)
SecondaryPercentage of Participants With Minimal Residual Disease (MRD) at Baseline and Day 50

After induction chemotherapy, based on bone marrow biopsies. No formal statistical analyses of MRD were performed for this study.

Time frame:
Baseline and Day 50
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) at Baseline and Day 50
percentage of participantsTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
At Baseline75NA
At Day 502511
SecondaryTime to CR

Disease response measurements were based on bone marrow evaluations (biopsies, aspirates, or both) performed by local pathology laboratories an assessed by study investigators. CR: requires that the participant achieved a morphologic leukemia-free state and had an ANC \>1000/mcL and platelets \>100,000/mcL. Hemoglobin concentration or hematocrit had no bearing on remission status, although the participant had to be independent of transfusions. Kaplan-Meier curves were used to describe time to CR.

Time frame:
Randomization to Day 50
Reported as:
Median · days
Time to CR
daysTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Time to CR43.0 (35.0 to NA)37.0 (32.0 to 40.0)
SecondaryTime to Neutrophil Recovery

Blood sampling was used to determine recovery, and is defined as less than or equal to 1000 per cubic millimeter (/mm\^3) for absolute neutrophil count (ANC). Summarized using Kaplan-Meier product limit estimators.

Time frame:
Baseline up to Day 50
Reported as:
Median · days
Time to Neutrophil Recovery
daysTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Time to Neutrophil Recovery26.0 (13.0 to 43.0)18.0 (15.0 to 25.0)
SecondaryTime to Platelet Recovery

Blood sampling was used to determine recovery and is defined as less than or equal to 100,000/mm\^3 for platelet count. Summarized using Kaplan-Meier product limit estimators.

Time frame:
Baseline up to Day 38
Reported as:
Median · days
Time to Platelet Recovery
daysTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
Time to Platelet Recovery22.0 (6.0 to 26.0)14.5 (8.0 to 18.0)

Adverse events

Collected over For each participant, from the time the participant signed the informed consent form until the AE resolved, or for 30 days after the participant's last study visit, whichever came first (approximately up to 2 years and 5 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Decitabine + Induction Chemotherapy3/11 (27.3%)2/11 (18.2%)8/11 (72.7%)
Treatment B: Induction Chemotherapy Only3/14 (21.4%)1/14 (7.1%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
AppendicitisInfections and infestations1/110/14
Large intestine perforationInjury, poisoning and procedural complications1/110/14
Lower gastrointestinal hemorrhageGastrointestinal disorders1/110/14
SepsisInfections and infestations0/111/14
Most frequent other events
Showing 10 of 195
Most frequent other events
EventTreatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy Only
AnaemiaBlood and lymphatic system disorders6/114/14
DiarrhoeaGastrointestinal disorders6/114/14
White blood cell count decreasedInvestigations6/115/14
Decreased appetiteMetabolism and nutrition disorders6/113/14
ConstipationGastrointestinal disorders5/112/14
VomitingGastrointestinal disorders5/113/14
Catheter site erythemaGeneral disorders5/112/14
HypotensionVascular disorders5/111/14
Abdominal painGastrointestinal disorders3/116/14
ThrombocytopeniaBlood and lymphatic system disorders4/112/14

Baseline characteristics

The full analysis set included all participants who received at least one dose of study treatment and who had at least one postdose efficacy measurement for response.

Age, Customized
Age, Customized(participants)Treatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy OnlyTotal
1 to less than (<) 2 years011
2 to 11 years7815
12 to 16 years459
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy OnlyTotal
Female7613
Male4812
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy OnlyTotal
Hispanic or Latino156
Not Hispanic or Latino10919
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment A: Decitabine + Induction ChemotherapyTreatment B: Induction Chemotherapy OnlyTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White81220
More than one race000
Unknown or Not Reported112
08

Study locations

22 sites
  • Phoenix, Arizona, United States
  • Madera, California, United States
  • Aurora, Colorado, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Rochester, Minnesota, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • New Lambton Heights, New South Wales, Australia
  • Westmead, New South Wales, Australia
  • Parkville, Victoria, Australia
  • Subiaco, Western Australia, Australia
  • Calgary, Alberta, Canada
09

References and documents

Publications

  • Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017 Oct 5;9:108. doi: 10.1186/s13148-017-0411-x. eCollection 2017. PubMed 29034009 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2011 to primary completion in Jul 2013, 28 months.

Results were first posted in Jun 2022, 8 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 9, 2010
StartActual
Mar 3, 2011
Primary completionActual
Jul 19, 2013
CompletionActual
Jul 19, 2013
Results first posted
Jun 28, 2022
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01177540
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Aug 9, 2010
Start date
Mar 3, 2011
Primary completion
Jul 19, 2013
Completion
Jul 19, 2013
Results posted
Jun 28, 2022
Last update
Jun 28, 2022

Study contacts

Eisai Medical Services
study director · Eisai Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion